FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer

Acta Pharmacologica Sinica

Volumn 34, Issue 4, 2013, Pages 549-554

  Fang, Hong Mei ^a   Tian, Gang ^b   Zhou, Li Juan ^a   Zhou, Han Ying ^a   Fang, Ying Zhi ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chinese population; Fibroblast growth factor receptor 4; Gene polymorphism; Non small cell lung cancer; Platinum based chemotherapy; Prognosis; Response to chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GENOMIC DNA; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME;

AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4;

EID: 84877310515     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.206     Document Type: Article

References (29)

1. Watanabe H, Yamamoto S, Kunitoh H, Sekine I, Yamamoto N, Ohe Y, et al. Tumor response to chemotherapy: The validity and reproducibility of RECIST guidelines in NSCLC patients. Cancer Sci 2003; 94: 1015-20 (Pubitemid 37508986)
2. Nakajima E, Katou H. Adjuvant chemotherapy for resectable nonsmall cell lung cancer (NSCLC). Kyobu Geka 2008; 61: 4-8
3. Perng RP, Yang CH, Chen YM, Chang GC, Lin MC, Hsieh RK, et al. High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer 2008; 62: 78-84
4. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011; 71: 3-10
5. Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010; 28: 4945-52
6. Cappuzzo F, Ligorio C, Toschi L, Rossi E, Trisolini R, Paioli D, et al. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007; 2: 423-9 (Pubitemid 47181697)
7. Wu J, Liu J, Zhou Y, Ying J, Zou H, Guo S, et al. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: A systematic review and meta-Analysis. Clin Cancer Res 2012; 18: 3972-81
8. Rosell R, Felip E, Taron M, Majo J, Mendez P, Sanchez-Ronco M, et al. Gene expression as a predictive marker of outcome in stage IIBIIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004; 10: 4215s-4219s. (Pubitemid 38812449)
9. Galzie Z, Kinsella AR, Smith JA. Fibroblast growth factors and their receptors. Biochem Cell Biol 1997; 75: 669-85 (Pubitemid 127733222)
10. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000; 7: 165-97
11. Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J 2011; 437: 199-213
12. Kornmann M, Beger HG, Korc M. Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas 1998; 17: 169-75 (Pubitemid 28345813)
13. Spinola M, Leoni VP, Tanuma J, Pettinicchio A, Frattini M, Signoroni S, et al. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol Rep 2005; 14: 415-9
14. Falvella FS, Frullanti E, Galvan A, Spinola M, Noci S, De Cecco L, et al. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int J Cancer 2009; 124: 2880-5
15. Ho CK, Anwar S, Nanda J, Habib FK. FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men. Prostate Cancer Prostatic Dis 2010; 13: 94-6
16. Xu B, Tong N, Chen SQ, Hua LX, Wang ZJ, Zhang ZD, et al. FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: A meta-Analysis of 2618 cases and 2305 controls. BMC Cancer 2011; 11: 84
17. Marme F, Hielscher T, Hug S, Bondong S, Zeillinger R, Castillo-Tong DC, et al. Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. Int J Cancer 2012; 131: E586-91
18. Wang J, Yu W, Cai Y, Ren C, Ittmann MM. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 2008; 10: 847-56
19. Zhang HF, Zhao KJ, Yang PF, Fang YB, Zhang YH, Liu JM, et al. Association between fibroblast growth factor receptor 4 Gly388Arg polymorphism and ischaemic stroke. J Int Med Res 2012; 40: 1708-14
20. Zhu Q, Liu T. Fibroblast growth factor receptor 4 polymorphisms and coronary artery disease: A case control study. Mol Biol Rep 2012; 39: 8679-85
21. Wong BS, Camilleri M, Carlson PJ, Odunsi-Shiyanbade S, McKinzie S, Busciglio I, et al. Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea. Dig Dis Sci 2012; 57: 1222-6
22. Yang Y, Zhou Y, Lu M, An Y, Li R, Chen Y, et al. Association between fibroblast growth factor receptor 4 polymorphisms and risk of hepatocellular carcinoma. Mol Carcinog 2012; 51: 515-21
23. Frullanti E, Berking C, Harbeck N, Jezequel P, Haugen A, Mawrin C, et al. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. Eur J Cancer Prev 2011; 20: 340-7
24. Heinzle C, Gsur A, Hunjadi M, Erdem Z, Gauglhofer C, Stattner S, et al. Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. Cancer Res 2012; 72: 5767-77
25. Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S, et al. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer 2008; 123: 2574-9
26. Liwei L, Chunyu L, Jie L, Ruifa H. Association between fibroblast growth factor receptor-4 gene polymorphism and risk of prostate cancer: A meta-Analysis. Urol Int 2011; 87: 159-64
27. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002; 62: 840-7 (Pubitemid 34126962)
28. Spinola M, Leoni V, Pignatiello C, Conti B, Ravagnani F, Pastorino U, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 2005; 23: 7307-11 (Pubitemid 46202344)
29. Marme F, Werft W, Benner A, Burwinkel B, Sinn P, Sohn C, et al. FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer. Ann Oncol 2010; 21: 1636-42